{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T21:12:03Z","timestamp":1778188323626,"version":"3.51.4"},"reference-count":109,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009731","name":"Sichuan Provincial Youth Science and Technology Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016809","name":"Bureau of Science and Technology Nanchong City","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.dmd.2026.100267","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T23:58:25Z","timestamp":1772841505000},"page":"100267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug-drug interactions induced by immunosuppressants through inhibition of human carboxylesterases"],"prefix":"10.1016","volume":"54","author":[{"given":"Yuxin","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenyuan","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzhi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenzhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3586-0233","authenticated-orcid":false,"given":"Zuo","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.dmd.2026.100267_bib1","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00178-24","article-title":"Immunosuppressant imprecision: multidirectional effects on metabolism and microbiome","volume":"38","author":"Kensiski","year":"2025","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"10.1016\/j.dmd.2026.100267_bib2","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1176\/appi.psy.45.4.354","article-title":"Immunosuppressants","volume":"45","author":"Fireman","year":"2004","journal-title":"Psychosomatics"},{"issue":"3","key":"10.1016\/j.dmd.2026.100267_bib3","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rdc.2024.03.006","article-title":"Newer immunosuppressants for rheumatologic disease: preoperative considerations","volume":"50","author":"Koh","year":"2024","journal-title":"Rheum Dis Clin"},{"issue":"6","key":"10.1016\/j.dmd.2026.100267_bib4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/ncpneuro0810","article-title":"Steroids and immunosuppressant drugs in myasthenia gravis","volume":"4","author":"Sathasivam","year":"2008","journal-title":"Nat Clin Pract Neurol"},{"issue":"12 Suppl 6","key":"10.1016\/j.dmd.2026.100267_bib5","first-page":"S41","article-title":"Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis","volume":"63","author":"Jeffery","year":"2004","journal-title":"Neurology"},{"issue":"10441","key":"10.1016\/j.dmd.2026.100267_bib6","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1016\/S0140-6736(24)00398-2","article-title":"Systemic lupus erythematosus","volume":"403","author":"Hoi","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.dmd.2026.100267_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/1753-0407.12090","article-title":"Glucocorticoid-induced hyperglycemia","volume":"6","author":"Perez","year":"2014","journal-title":"J Diabetes"},{"issue":"1","key":"10.1016\/j.dmd.2026.100267_bib8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1517\/14728214.8.1.47","article-title":"Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases","volume":"8","author":"Kovarik","year":"2003","journal-title":"Expert Opin Emerg Drugs"},{"issue":"11","key":"10.1016\/j.dmd.2026.100267_bib9","first-page":"1939","article-title":"Clinical views from the forefront of immunosuppressive drugs","volume":"63","author":"Kobayashi","year":"2005","journal-title":"Nihon Rinsho"},{"issue":"12","key":"10.1016\/j.dmd.2026.100267_bib10","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.3390\/ph14121256","article-title":"Antirheumatic drugs against COVID-19 from the perspective of rheumatologists","volume":"14","author":"Kawazoe","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"10.1016\/j.dmd.2026.100267_bib11","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.3892\/ijo.2013.1906","article-title":"Combination of FTY720 with cisplatin exhibits antagonistic effects in ovarian cancer cells: role of autophagy","volume":"42","author":"Zhang","year":"2013","journal-title":"Int J Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.dmd.2026.100267_bib12","first-page":"S41","article-title":"Mitoxantrone and cytotoxic drugs' mechanisms of action","volume":"74","author":"Vollmer","year":"2010","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.dmd.2026.100267_bib13","doi-asserted-by":"crossref","first-page":"6773","DOI":"10.3390\/ijms23126773","article-title":"Mechanisms of sensitivity and resistance of primary effusion lymphoma to dimethyl fumarate (DMF)","volume":"23","author":"Gonnella","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.dmd.2026.100267_bib14","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","article-title":"The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells","volume":"58","author":"Galustian","year":"2009","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"10.1016\/j.dmd.2026.100267_bib15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1046\/j.1365-2613.2002.00219.x","article-title":"Antiproliferative effect of thalidomide alone and combined with carmustine against C6 rat glioma","volume":"83","author":"Arrieta","year":"2002","journal-title":"Int J Exp Pathol"},{"issue":"7","key":"10.1016\/j.dmd.2026.100267_bib16","doi-asserted-by":"crossref","DOI":"10.1111\/apha.14161","article-title":"How calcineurin inhibitors affect cognition","volume":"240","author":"Thiankhaw","year":"2024","journal-title":"Acta Physiol"},{"issue":"5","key":"10.1016\/j.dmd.2026.100267_bib17","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a025924","article-title":"Inhibition of the mechanistic target of rapamycin (mTOR)-rapamycin and beyond","volume":"6","author":"Lamming","year":"2016","journal-title":"Cold Spring Harbor Perspect Med"},{"key":"10.1016\/j.dmd.2026.100267_bib18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1054-3589(08)60593-1","article-title":"An introduction to immunosuppressants","volume":"8","author":"Aisenberg","year":"1970","journal-title":"Adv Pharmacol Chemother"},{"issue":"1","key":"10.1016\/j.dmd.2026.100267_bib19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40265-021-01643-6","article-title":"Avacopan: first approval","volume":"82","author":"Lee","year":"2022","journal-title":"Drugs"},{"issue":"20","key":"10.1016\/j.dmd.2026.100267_bib20","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.3390\/cancers13205154","article-title":"Relapsed\/refractory multiple myeloma in 2020\/2021 and beyond","volume":"13","author":"Podar","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.dmd.2026.100267_bib21","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/08923973.2021.1966033","article-title":"Transplantation and immunosuppression: a review of novel transplant-related immunosuppressant drugs","volume":"43","author":"Parlakpinar","year":"2021","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"11","key":"10.1016\/j.dmd.2026.100267_bib22","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1093\/ndt\/15.11.1865","article-title":"Low dose aspirin as prophylaxis against renal-vein thrombosis in renal-transplant recipients","volume":"15","author":"Robertson","year":"2000","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.dmd.2026.100267_bib23","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/00007890-200209270-00026","article-title":"TTP\/HUS occurring in a simultaneous pancreas\/kidney transplant recipient after clopidogrel treatment: evidence of a nonimmunological etiology","volume":"74","author":"Evens","year":"2002","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.dmd.2026.100267_bib24","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1136\/ard-2022-223736","article-title":"Combined therapy of prednisone and mTOR inhibitor sirolimus for treating retroperitoneal fibrosis","volume":"82","author":"Gao","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"20","key":"10.1016\/j.dmd.2026.100267_bib25","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.4045\/tidsskr.11.0138","article-title":"Drug interactions and immunosuppression in organ transplant recipients","volume":"131","author":"Vethe","year":"2011","journal-title":"Tidsskr Nor Laegeforen"},{"issue":"8","key":"10.1016\/j.dmd.2026.100267_bib26","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.2215\/CJN.15040920","article-title":"Long-term immunosuppression management: opportunities and uncertainties","volume":"16","author":"Wojciechowski","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100267_bib27","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJM199707173370302","article-title":"Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss","volume":"337","author":"Laskin","year":"1997","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.dmd.2026.100267_bib28","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13833","article-title":"Signal of safety due to adverse drug reactions induced by tacrolimus with or without azithromycin","volume":"24","author":"Yonezawa","year":"2022","journal-title":"Transpl Infect Dis"},{"issue":"4","key":"10.1016\/j.dmd.2026.100267_bib29","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00280-005-1020-5","article-title":"Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer","volume":"56","author":"Desai","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100267_bib30","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2165\/11593800-000000000-00000","article-title":"Comparing antihypertensive effect and plasma ciclosporin concentration between amlodipine and valsartan regimens in hypertensive renal transplant patients receiving ciclosporin therapy","volume":"11","author":"Cai","year":"2011","journal-title":"Am J Cardiovasc Drugs"},{"issue":"5","key":"10.1016\/j.dmd.2026.100267_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-229587","article-title":"Cyclosporine A and amlodipine induced gingival overgrowth in a kidney transplant recipient: case presentation with literature review","volume":"12","author":"Nanda","year":"2019","journal-title":"BMJ Case Rep"},{"issue":"4","key":"10.1016\/j.dmd.2026.100267_bib32","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/clpt.2011.4","article-title":"Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers","volume":"89","author":"Oswald","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.dmd.2026.100267_bib33","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00787-012-0330-5","article-title":"Depression with psychotic features in a child with SLE: successful therapy with psychotropic medications--case report","volume":"22","author":"Milovancevic","year":"2013","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"4","key":"10.1016\/j.dmd.2026.100267_bib34","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2165\/00003495-200363040-00003","article-title":"Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients","volume":"63","author":"Asberg","year":"2003","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.dmd.2026.100267_bib35","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/clpt.2009.266","article-title":"Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers","volume":"87","author":"Oswald","year":"2010","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.dmd.2026.100267_bib36","first-page":"10","article-title":"Posttransplant tuberculosis","volume":"15","author":"Demir","year":"2017","journal-title":"Exp Clin Transplant"},{"issue":"3","key":"10.1016\/j.dmd.2026.100267_bib37","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s11096-022-01385-9","article-title":"Potential drug-drug interactions of immunosuppressants in kidney transplant recipients: comparison of drug interaction resources","volume":"44","author":"Pehlivanli","year":"2022","journal-title":"Int J Clin Pharm"},{"issue":"11 Suppl 1","key":"10.1016\/j.dmd.2026.100267_bib38","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1053\/jlts.2001.28512","article-title":"Long-term immunosuppression and drug interactions","volume":"7","author":"Levy","year":"2001","journal-title":"Liver Transpl"},{"issue":"1","key":"10.1016\/j.dmd.2026.100267_bib39","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1124\/pr.115.011411","article-title":"Role of cytochrome P450 2C8 in drug metabolism and interactions","volume":"68","author":"Backman","year":"2016","journal-title":"Pharmacol Rev"},{"issue":"1","key":"10.1016\/j.dmd.2026.100267_bib40","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s40262-023-01322-7","article-title":"Interplay of UDP-glucuronosyltransferase and CYP2C8 for CYP2C8 mediated drug oxidation and its impact on drug-drug interaction produced by standardized CYP2C8 inhibitors, clopidogrel and gemfibrozil","volume":"63","author":"Iga","year":"2024","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.dmd.2026.100267_bib41","doi-asserted-by":"crossref","first-page":"340","DOI":"10.2174\/1568026616666160829161934","article-title":"The role of metabolizing enzymes and transporters in antiretroviral therapy","volume":"17","author":"Ye","year":"2017","journal-title":"Curr Topics Med Chem"},{"key":"10.1016\/j.dmd.2026.100267_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2024.105833","article-title":"Evaluation of the inhibitory effects of antigout drugs on human carboxylesterases in vitro","volume":"98","author":"Liang","year":"2024","journal-title":"Toxicol In Vitro"},{"issue":"3","key":"10.1016\/j.dmd.2026.100267_bib43","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1124\/dmd.119.089680","article-title":"Carboxylesterase 1 and precision pharmacotherapy: pharmacogenetics and nongenetic regulators","volume":"48","author":"Her","year":"2020","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100267_bib44","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2174\/1389200219666180821094502","article-title":"The impact of carboxylesterases in drug metabolism and pharmacokinetics","volume":"20","author":"Di","year":"2019","journal-title":"Curr Drug Metab"},{"issue":"12","key":"10.1016\/j.dmd.2026.100267_bib45","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1124\/dmd.110.034249","article-title":"Involvement of carboxylesterase 1 and 2 in the hydrolysis of mycophenolate mofetil","volume":"38","author":"Fujiyama","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100267_bib46","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/0091270009343005","article-title":"Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans","volume":"50","author":"Farid","year":"2010","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100267_bib47","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1124\/dmd.113.054353","article-title":"Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis","volume":"42","author":"Laizure","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100267_bib48","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1124\/dmd.113.053512","article-title":"In vitro drug metabolism by human carboxylesterase 1: focus on angiotensin-converting enzyme inhibitors","volume":"42","author":"Thomsen","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"1-2","key":"10.1016\/j.dmd.2026.100267_bib49","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0731-7085(01)00508-8","article-title":"Kinetics of the acidic and enzymatic hydrolysis of benazepril HCl studied by LC","volume":"27","author":"Gana","year":"2002","journal-title":"J Pharm Biomed Anal"},{"issue":"12","key":"10.1016\/j.dmd.2026.100267_bib50","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1124\/dmd.110.034454","article-title":"In vitro evaluation of inhibitory effects of antidiabetic and antihyperlipidemic drugs on human carboxylesterase activities","volume":"38","author":"Fukami","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100267_bib51","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1248\/bpb.b14-00679","article-title":"Carboxylesterase 1-mediated drug-drug interactions between clopidogrel and simvastatin","volume":"38","author":"Wang","year":"2015","journal-title":"Biol Pharm Bull"},{"issue":"3","key":"10.1016\/j.dmd.2026.100267_bib52","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1124\/jpet.106.111807","article-title":"Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel","volume":"319","author":"Shi","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.dmd.2026.100267_bib53","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nsb790","article-title":"Structural insights into CPT-11 activation by mammalian carboxylesterases","volume":"9","author":"Bencharit","year":"2002","journal-title":"Nat Struct Biol"},{"issue":"5","key":"10.1016\/j.dmd.2026.100267_bib54","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/00498250902769967","article-title":"In vitro stability and metabolism of salvinorin A in rat plasma","volume":"39","author":"Tsujikawa","year":"2009","journal-title":"Xenobiotica"},{"issue":"2","key":"10.1016\/j.dmd.2026.100267_bib55","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/phar.1194","article-title":"The role of human carboxylesterases in drug metabolism: have we overlooked their importance?","volume":"33","author":"Laizure","year":"2013","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.dmd.2026.100267_bib56","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/sj.cgt.7701112","article-title":"An improved human carboxylesterase for enzyme\/prodrug therapy with CPT-11","volume":"15","author":"Wierdl","year":"2008","journal-title":"Cancer Gene Ther"},{"issue":"2","key":"10.1016\/j.dmd.2026.100267_bib57","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1124\/jpet.111.188508","article-title":"Carboxylesterases 1 and 2 hydrolyze phospho-nonsteroidal anti-inflammatory drugs: relevance to their pharmacological activity","volume":"340","author":"Wong","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.dmd.2026.100267_bib58","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3389\/fphar.2018.00104","article-title":"A mechanistic overview of triptolide and celastrol, natural products from Tripterygium wilfordii Hook F","volume":"9","author":"Chen","year":"2018","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.dmd.2026.100267_bib59","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nsb919","article-title":"Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme","volume":"10","author":"Bencharit","year":"2003","journal-title":"Nat Struct Biol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100267_bib60","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nchembio.1429","article-title":"Integrated phenotypic and activity-based profiling links Ces3 to obesity and diabetes","volume":"10","author":"Dominguez","year":"2014","journal-title":"Nat Chem Biol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100267_bib61","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/dmd.108.024943","article-title":"Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants","volume":"37","author":"Zhu","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.dmd.2026.100267_bib62","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1124\/dmd.122.000918","article-title":"The COVID-19 oral drug molnupiravir is a CES2 substrate: potential drug-drug interactions and impact of CES2 genetic polymorphism in vitro","volume":"50","author":"Shen","year":"2022","journal-title":"Drug Metab Dispos"},{"issue":"14","key":"10.1016\/j.dmd.2026.100267_bib63","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.2174\/0929867325666171204155558","article-title":"Carboxylesterase inhibitors: an update","volume":"25","author":"Zou","year":"2018","journal-title":"Curr Med Chem"},{"issue":"Pt A","key":"10.1016\/j.dmd.2026.100267_bib64","article-title":"Per- and polyfluoroalkyl substances exert strong inhibition towards human carboxylesterases","volume":"263","author":"Liu","year":"2020","journal-title":"Environ Pollut"},{"issue":"8","key":"10.1016\/j.dmd.2026.100267_bib65","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1124\/dmd.111.039628","article-title":"Characterization of recombinant human carboxylesterases: fluorescein diacetate as a probe substrate for human carboxylesterase 2","volume":"39","author":"Wang","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100267_bib66","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bios.2014.01.049","article-title":"A highly selective ratiometric fluorescent probe for in vitro monitoring and cellular imaging of human carboxylesterase 1","volume":"57","author":"Liu","year":"2014","journal-title":"Biosens Bioelectron"},{"issue":"1","key":"10.1016\/j.dmd.2026.100267_bib67","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.saa.2009.04.017","article-title":"Kinetic study of the complex reaction between copper(II) and 2-(2'-hydroxy-3'-methoxyphenyl)benzothiazole","volume":"74","author":"Freinbichler","year":"2009","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"},{"issue":"6","key":"10.1016\/j.dmd.2026.100267_bib68","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3109\/00498254.2015.1091521","article-title":"Inhibition behavior of fructus psoraleae's ingredients towards human carboxylesterase 1 (hCES1)","volume":"46","author":"Sun","year":"2016","journal-title":"Xenobiotica"},{"key":"10.1016\/j.dmd.2026.100267_bib69","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.fitote.2015.01.004","article-title":"Fructus Psoraleae contains natural compounds with potent inhibitory effects towards human carboxylesterase 2","volume":"101","author":"Li","year":"2015","journal-title":"Fitoterapia"},{"issue":"2","key":"10.1016\/j.dmd.2026.100267_bib70","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/wcms.1121","article-title":"An overview of the Amber biomolecular simulation package","volume":"3","author":"Salomon-Ferrer","year":"2013","journal-title":"Wiley Interdiscip Rev Comput Mol Sci"},{"key":"10.1016\/j.dmd.2026.100267_bib71","series-title":"gaussian 09, Revision d. 01. Gaussian","first-page":"201","author":"Frisch","year":"2009"},{"issue":"1","key":"10.1016\/j.dmd.2026.100267_bib72","article-title":"Antechamber: an accessory software package for molecular mechanical calculations","volume":"222","author":"Wang","year":"2001","journal-title":"J Am Chem Soc"},{"issue":"9","key":"10.1016\/j.dmd.2026.100267_bib73","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jcc.20035","article-title":"Development and testing of a general amber force field","volume":"25","author":"Wang","year":"2004","journal-title":"J Comput Chem"},{"issue":"8","key":"10.1016\/j.dmd.2026.100267_bib74","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","article-title":"ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB","volume":"11","author":"Maier","year":"2015","journal-title":"J Chem Theory computation"},{"key":"10.1016\/j.dmd.2026.100267_bib75","doi-asserted-by":"crossref","first-page":"9954","DOI":"10.1021\/jp003020w","article-title":"Structure and dynamics of the TIP3P, SPC, and SPC\/E water models at 298 K","volume":"105","author":"Mark","year":"2001","journal-title":"J Phys Chem A"},{"issue":"10","key":"10.1016\/j.dmd.2026.100267_bib76","doi-asserted-by":"crossref","DOI":"10.1063\/1.2464095","article-title":"Langevin stabilization of molecular-dynamics simulations of polymers by means of quasisymplectic algorithms","volume":"126","author":"Larini","year":"2007","journal-title":"J Chem Phys"},{"issue":"5","key":"10.1016\/j.dmd.2026.100267_bib77","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/1096-987X(20010415)22:5<501::AID-JCC1021>3.0.CO;2-V","article-title":"A fast SHAKE algorithm to solve distance constraint equations for small molecules in molecular dynamics simulations","volume":"22","author":"Kr\u00e4utler","year":"2001","journal-title":"J Comput Chem"},{"issue":"17","key":"10.1016\/j.dmd.2026.100267_bib78","doi-asserted-by":"crossref","first-page":"9656","DOI":"10.1039\/D0CP00831A","article-title":"The application of the MM\/GBSA method in the binding pose prediction of FGFR inhibitors","volume":"22","author":"Chen","year":"2020","journal-title":"Phys Chem Chem Phys"},{"issue":"1","key":"10.1016\/j.dmd.2026.100267_bib79","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1021\/ci100275a","article-title":"Assessing the performance of the MM\/PBSA and MM\/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations","volume":"51","author":"Hou","year":"2011","journal-title":"J Chem Inf Model"},{"issue":"5","key":"10.1016\/j.dmd.2026.100267_bib80","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","article-title":"The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities","volume":"10","author":"Genheden","year":"2015","journal-title":"Expert Opin Drug Discov"},{"issue":"4","key":"10.1016\/j.dmd.2026.100267_bib81","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/jcc.21372","article-title":"Fast and accurate predictions of binding free energies using MM-PBSA and MM-GBSA","volume":"31","author":"Rastelli","year":"2010","journal-title":"J Comput Chem"},{"issue":"6","key":"10.1016\/j.dmd.2026.100267_bib82","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s40262-014-0226-2","article-title":"Effects of alcohol on human carboxylesterase drug metabolism","volume":"54","author":"Parker","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.dmd.2026.100267_bib83","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/17425255.2024.2348491","article-title":"Regulation of carboxylesterases and its impact on pharmacokinetics and pharmacodynamics: an up-to-date review","volume":"20","author":"Liu","year":"2024","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.dmd.2026.100267_bib84","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jpba.2018.12.020","article-title":"Development of stability-indicating HPLC method and accelerated stability studies for osmotic and pulsatile tablet formulations of clopidogrel bisulfate","volume":"165","author":"Deshmukh","year":"2019","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.dmd.2026.100267_bib85","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0021-9673(01)91690-5","article-title":"Simultaneous high-performance liquid chromatography assay of acetylsalicylic acid and salicylic acid in film-coated aspirin tablets","volume":"317","author":"Fogel","year":"1984","journal-title":"J Chromatogr"},{"issue":"1","key":"10.1016\/j.dmd.2026.100267_bib86","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s12272-011-0107-2","article-title":"Simultaneous determination of mycophenolic acid and its metabolites by HPLC and pharmacokinetic studies in rat plasma and bile","volume":"34","author":"Gao","year":"2011","journal-title":"Arch Pharm Res"},{"issue":"8","key":"10.1016\/j.dmd.2026.100267_bib87","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1517\/14656566.2011.550573","article-title":"Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor","volume":"12","author":"Giorgi","year":"2011","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"10.1016\/j.dmd.2026.100267_bib88","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF00558267","article-title":"Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function","volume":"35","author":"Bochner","year":"1988","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100267_bib89","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/j.1552-4604.1996.tb04207.x","article-title":"Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration","volume":"36","author":"Bullingham","year":"1996","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.dmd.2026.100267_bib90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164646","article-title":"Characterization of pharmacologic and pharmacokinetic properties of CCX168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and randomized phase 1 clinical study","volume":"11","author":"Bekker","year":"2016","journal-title":"PloS One"},{"issue":"7","key":"10.1016\/j.dmd.2026.100267_bib91","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1097\/01.TP.0000084822.01372.AC","article-title":"Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study","volume":"76","author":"Kahan","year":"2003","journal-title":"Transplantation"},{"issue":"34","key":"10.1016\/j.dmd.2026.100267_bib92","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1200\/JCO.2015.65.3949","article-title":"First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors","volume":"34","author":"Abdul Razak","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100267_bib93","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00003088-200443020-00002","article-title":"Clinical pharmacokinetics of everolimus","volume":"43","author":"Kirchner","year":"2004","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.dmd.2026.100267_bib94","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2165\/00003088-199529060-00003","article-title":"Clinical pharmacokinetics of tacrolimus","volume":"29","author":"Venkataramanan","year":"1995","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.dmd.2026.100267_bib95","doi-asserted-by":"crossref","first-page":"106","DOI":"10.2174\/1871525721666230726150021","article-title":"Tacrolimus and cyclosporin pharmacotherapy, detection methods, cytochrome P450 enzymes after heart transplantation","volume":"22","author":"Tolou-Ghamari","year":"2024","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"issue":"3","key":"10.1016\/j.dmd.2026.100267_bib96","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1515\/dmdi-2014-0009","article-title":"The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect","volume":"29","author":"Merali","year":"2014","journal-title":"Drug Metab Drug Interact"},{"key":"10.1016\/j.dmd.2026.100267_bib97","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/6139253","article-title":"Pros and cons of aspirin prophylaxis for prevention of cardiovascular events in kidney transplantation and review of evidence","volume":"2019","author":"Khalil","year":"2019","journal-title":"Adv Prev Med"},{"issue":"7","key":"10.1016\/j.dmd.2026.100267_bib98","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S1470-2045(17)30355-8","article-title":"Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial","volume":"18","author":"Mody","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.dmd.2026.100267_bib99","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.apsb.2018.05.005","article-title":"Human carboxylesterases: a comprehensive review","volume":"8","author":"Wang","year":"2018","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.dmd.2026.100267_bib100","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.bioorg.2018.01.011","article-title":"Characterization and structure-activity relationship studies of flavonoids as inhibitors against human carboxylesterase 2","volume":"77","author":"Weng","year":"2018","journal-title":"Bioorg Chem"},{"issue":"2","key":"10.1016\/j.dmd.2026.100267_bib101","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.apsb.2022.10.017","article-title":"Carboxylesterase 1 family knockout alters drug disposition and lipid metabolism","volume":"13","author":"Gan","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.dmd.2026.100267_bib102","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.cbi.2019.06.003","article-title":"Inhibition of human carboxylesterases by magnolol: kinetic analyses and mechanism","volume":"308","author":"Song","year":"2019","journal-title":"Chem Biol Interact"},{"issue":"2","key":"10.1016\/j.dmd.2026.100267_bib103","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s13238-017-0437-z","article-title":"Carboxylesterases in lipid metabolism: from mouse to human","volume":"9","author":"Lian","year":"2018","journal-title":"Protein Cell"},{"issue":"5","key":"10.1016\/j.dmd.2026.100267_bib104","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1080\/00498254.2017.1335917","article-title":"Everolimus-inhibited multiple isoforms of UDP-glucuronosyltransferases (UGTs)","volume":"48","author":"Du","year":"2018","journal-title":"Xenobiotica"},{"issue":"8","key":"10.1016\/j.dmd.2026.100267_bib105","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1124\/dmd.121.000476","article-title":"Quantitative investigation of irinotecan metabolism, transport, and gut microbiome activation","volume":"49","author":"Parvez","year":"2021","journal-title":"Drug Metab Dispos"},{"issue":"5 Pt 2 Suppl","key":"10.1016\/j.dmd.2026.100267_bib106","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1542\/peds.62.5S.867","article-title":"Clinical pharmacokinetics of aspirin","volume":"62","author":"Levy","year":"1978","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.dmd.2026.100267_bib107","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003088-198917050-00003","article-title":"Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid","volume":"17","author":"Miners","year":"1989","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.dmd.2026.100267_bib108","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s001050050013","article-title":"Mycophenolate mofetil: a new immunosuppressive drug in dermatology and its possible uses","volume":"51","author":"Geilen","year":"2000","journal-title":"Hautarzt"},{"issue":"3 Pt 1","key":"10.1016\/j.dmd.2026.100267_bib109","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0190-9622(18)30747-3","article-title":"Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses","volume":"37","author":"Kitchin","year":"1997","journal-title":"J Am Acad Dermatol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562600036X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562600036X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T20:46:12Z","timestamp":1778186772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009095562600036X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":109,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S009095562600036X"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100267","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-drug interactions induced by immunosuppressants through inhibition of human carboxylesterases","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100267","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100267"}}